NRG-HN010, A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer (NCT05408845)
Details
Age
Adult
Type of Study
Treatment
Locations
Highlands Ranch Hospital
University of Colorado Hospital
Principal Investigator
Daniel Bowles, MD
Study ID
Protocol Number: 22-2363
More information available at ClinicalTrials.gov: NCT05408845
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers